Drugs to Watch in 2024

2024 Drugs to Watch – What Is Fuelling Medical Breakthroughs of the Future?

The Clarivate Drugs to Watch™ report spotlights recently launched or soon-to-launch drugs with the potential to change treatment paradigms and/or reach blockbuster status within five years.

This year’s Drugs to Watch™ report from Clarivate spotlights 13 drugs set to make a mark in 2024, including those expected to reach blockbuster status as well as those with the potential to transform treatment paradigms and serve unmet patient needs. 

Download the report to uncover:

  • Newly-approved or soon-to-be-approved drugs set to establish themselves as breakthrough medicines and blockbuster revenue generators
  • Emerging trends consequential to the discovery, development and delivery of new medicines
  • New technologies such as CRISPR-Cas9 gene-editing and artificial intelligence (AI)/machine learning (ML) applications that hold enormous potential to help drugmakers cut costs and shorten innovation cycles.

Methodology

To identify this year’s Drugs to Watch 2024 list, we drew from expertise from over 160 Clarivate analysts covering hundreds of diseases, drugs and markets and eleven integrated data sets that span the R&D and commercialization lifecycle.

Clarivate experts then manually evaluated each drug in its individual context, based on factors such as expected approval or launch dates, competitive landscape, regulatory status, trial results, market dynamics and other factors and added novel drugs that, while likely to fall short of blockbuster status, are poised to be therapeutic game-changers.

Drug selection criteria

  • Candidate drugs in phase 2 or phase 3 trials, at pre-registration or registration stage or already launched early in 2023 were selected for analysis, including drugs launched for a new indication that could be particularly impactful on the industry; drugs launched prior to 2023 were excluded.
  • The dataset was then filtered for drugs that had total forecast sales of $1 billion or more in 2029.
  • Expert analysts then added recently launched and soon-to-launch therapeutics set to significantly transform treatment paradigms, even if they are not forecast to be blockbusters within five years.

Download the report as it unveils the 13 identified drugs which according to Clarivate experts have the potential to be the new frontiers in medicine and the key trends that will transform treatment paradigms.

You can also join an exclusive webinar on February 21st as Clarivate’s experts deep dive into the 2024 Drugs to Watch report. Register here.

News & Trends - MedTech & Diagnostics

Government commissions review as 70% of private hospitals face financial crisis

Government commissions review as 70% of private hospitals face financial crisis

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: Despite playing a crucial role in providing acute care and surgical services, a staggering 70% of […]

More


News & Trends - Pharmaceuticals

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Health Industry Hub | June 14, 2024 |

Pharma News: The Pharmacy Guild of Australia has echoed the significant concerns of the Australian Competition and Consumer Commission (ACCC) […]

More


News & Trends - MedTech & Diagnostics

Competition watchdog raises concerns over cancer care provider's expansion plans

Competition watchdog raises concerns over cancer care provider’s expansion plans

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: A leading provider of cancer care services in Australia, faces scrutiny from the Australian Competition and […]

More


News & Trends - Biotechnology

Aussie biotech secures first local CAR T patent

Aussie biotech secures first local CAR T patent

Health Industry Hub | June 13, 2024 |

Biotech News: A Melbourne-based biotechnology company which specialises in developing immune cell therapies for cancer treatment, has been granted its […]

More


This content is copyright protected. Please subscribe to gain access.